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A B S T R A C T
Purpose: To investigate changes in the choice of ﬁrst anti-epileptic drug (AED) and co-prescription of
folic acid after a new diagnosis of epilepsy.
Methods: We searched anonymised electronic primary care records dating between 2000 and 2010 for
patients with a new diagnosis of epilepsy and recorded the ﬁrst AED prescribed and whether folic acid
was co-prescribed.
Results: From 13.3 million patient years of primary care records, we identiﬁed 3714 patients with a new
diagnosis of epilepsy (925 children and 649 women aged 14–45 years). Comparing ﬁrst time AED
prescriptions in 2000 and 2001 to those in 2009 and 2010 showed a signiﬁcant decrease in the
proportion of carbamazepine and phenytoin prescribed and a signiﬁcant increase in the proportion of
lamotrigine and levetiracetam prescribed. In women aged 14–45 years, and girls aged <18 there was a
signiﬁcant decrease in the proportion of sodium valproate prescribed. Women aged 14–45 years were
signiﬁcantly more likely to be co-prescribed folic acid with their ﬁrst AED compared to all other patients
(20% vs 3%, p-value < 0.001). The proportion of folic acid co-prescribed with the ﬁrst AED did not change
signiﬁcantly between 2000 and 2010.
Conclusion: The changing trends in the ﬁrst AED prescribed over the last decade, particularly in women
of childbearing age, reﬂect published evidence in terms of AED efﬁcacy, tolerability and safety.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Several factors have inﬂuenced the selection of appropriate
anti-epileptic drugs (AEDs) to treat epilepsy during the last decade.
The side effect proﬁles of older AEDs are less acceptable when
compared with newer AEDs.1 Randomised controlled trials have
directly compared the efﬁciency and tolerability of AEDs. For
example, the SANAD trial recommended lamotrigine as ﬁrst line
treatment for focal epilepsies and sodium valproate as the ﬁrst line
treatment for generalised or unclassiﬁed epilepsy.2 Several new
effective AEDs have become available e.g. eslicarbazepine acetate,
lacosamide, levetiracetam, oxcarbazepine, pregabalin, ruﬁnamide,
and zonisamide. Potentially harmful effects of certain AEDs on the* Corresponding author at: Clinical Research Fellow, 3rd Floor, Institute of Life
Sciences, Swansea University, Swansea SA2 8PP, UK. Tel.: +44 01792 295134;
fax: +44 01792 602280.
E-mail address: w.o.pickrell@swansea.ac.uk (W.O. Pickrell).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.09.007cognitive and physical health of the unborn and developing child
are increasingly recognised – in particular sodium valproate.3,4
National guidelines have recommended the co-prescription of folic
acid with AEDs for women who may become pregnant.5
In the UK, every individual is assigned a National Health
Service (NHS) general practitioner (GP). GPs prescribe the vast
majority of AEDs in the UK. To ensure that patients with epilepsy
receive the best treatment, it is important to know whether actual
prescribing practice reﬂects current best recommended practice.
A patient with epilepsy and good seizure control on an established
AED is not often changed to a potentially more suitable AED, given
the risk of seizure recurrence. We therefore speciﬁcally looked at
the trends of ﬁrst time prescriptions of AEDs using GP records in
Wales, UK.
2. Methods
GP primary care electronic health records are stored within the
Medical Research Council Centre for Informatics and Public Healthvier Ltd. All rights reserved.
W.O. Pickrell et al. / Seizure 23 (2014) 77–8078Research (CiPHER) at Swansea University, UK, as part of the Secure
Anonymised Information Linkage (SAIL) system.6,7 At the time of
analysis, the SAIL system had approximately 40% of the Welsh
population’s GP records available (around 1.1 million people).
We electronically searched all SAIL records for patients with a
diagnosis of epilepsy recorded for the ﬁrst time between 1st
January 2000 and 31st December 2010, and who were prescribed
an AED for the ﬁrst time on at least two consecutive occasions
within 12 months of the diagnosis date. For each patient matching
these criteria, we recorded the ﬁrst AED prescribed, together with
their age, sex, year of diagnosis and whether folic acid was co-
prescribed. (It is not possible to obtain accurately the type of
epilepsy from the GP records). We grouped the data into the
following age categories: children (aged 0–17 years); adults
(aged  18 years) and women of child-bearing age (deﬁned as aged
between 14 and 45 years). We plotted trends in AED prescriptions
and calculated correlation coefﬁcients. We also compared the
proportions of AEDs prescribed in 2000 and 2001 compared to
those prescribed in 2009 and 2010. Pearson’s product-moment● ●
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Fig. 1. (a) First AED prescribed as a proportion of all ﬁrst AED prescriptions by year betw
Proportion of ﬁrst AED prescriptions having a co-prescription of folic acid between 2
phenytoin; VPA, sodium valproate).correlation and proportion tests were calculated using the
statistical software package R version 2.15.2.
Due to anonymisation issues, we excluded AEDs which
constituted <2% of total prescriptions – these included ethosux-
imide, gabapentin, oxcarbazepine, phenobarbital, topiramate and
zonisamide.
This study was approved by the HIRU information governance
panel (Project 0202). The National Research Ethics Service has
conﬁrmed that HIRU projects using anonymised data do not
require speciﬁc NHS research ethics committee approval.
3. Results
We analysed 13.3 million patient years of GP records (a mean of
1.2 million patients every year between 2000 and 2010) and
identiﬁed 3714 patients with a new diagnosis of epilepsy who met
the inclusion criteria. Of these, there were 2722 adults (aged  18
years); 992 children (aged 0–17 years); and 649 women of
childbearing age (14–45 years of age). Fig. 1 shows trends in AED●
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Table 1
Number of prescriptions of each drug and folic acid in years 2000 and 2001 combined and in 2009 and 2010 combined.
Category 2000 + 2001 combined 2009 + 2010 combined P-value Correlation coefﬁcient 2000–2010b
All CBZ 121 (23%) 97 (15%) 0.002a 0.94 (0.99, 0.78)
LEV 0 (0%) 49 (8%) <0.001a 0.83 (0.48, 0.96)
LTG 55 (10%) 150 (24%) <0.001a 0.88 (0.59, 0.97)
PHT 62 (12%) 31 (5%) <0.001a 0.83 (0.95, 0.46)
VPA 298 (56%) 307 (48%) 0.017 0.64 (0.90, 0.07)
FOL 23 (4%) 51 (8%) 0.012 0.48 (0.14, 0.84)
Children (<18 years) FOL 3 (2%) 10 (5%) 0.169 0.34 (0.32, 0.78)
Boys (<18 years) CBZ 11 (13%) 11 (12%) 1.000 0.10 (0.66, 0.53)
LEV 0 (0%) 6 (6%) 0.049 0.66 (0.10, 0.90)
LTG 9 (10%) 6 (6%) 0.471 0.07 (0.56, 0.64)
VPA 66 (77%) 71 (76%) 0.988 0.37 (0.78, 0.28)
Girls (<18 years) CBZ 10 (15%) 9 (9%) 0.395 0.58 (0.87, 0.03)
LEV 0 (0%) 9 (9%) 0.026 0.66 (0.09, 0.90)
LTG 7 (11%) 33 (35%) <0.001a 0.82 (0.44, 0.95)
VPA 49 (74%) 44 (46%) <0.001a 0.76 (0.93, 0.29)
Women (14–45 years) CBZ 28 (26%) 16 (14%) 0.042 0.64 (0.89, 0.06)
LEV 0 (0%) 14 (13%) <0.001a 0.79 (0.37, 0.94)
LTG 26 (25%) 51 (46%) 0.002a 0.84 (0.48, 0.96)
PHT 4 (4%) 3 (3%) 0.951 0.25 (0.74, 0.41)
VPA 48 (45%) 27 (24%) 0.001a 0.87 (0.97, 0.57)
FOL 14 (13%) 31 (28%) 0.062 0.51 (0.12, 0.85)
Men (14–45 years) CBZ 34 (32%) 23 (17%) 0.014 0.80 (0.94, 0.38)
LEV 0 (0%) 12 (9%) 0.004 0.86 (0.54, 0.96)
LTG 12 (11%) 37 (28%) 0.003 0.74 (0.26, 0.93)
PHT 8 (7%) 4 (3%) 0.200 0.56 (0.86, 0.05)
VPA 53 (50%) 57 (43%) 0.367 0.15 (0.69, 0.50)
FOL 0 (0%) 3 (2%) 0.310 0.22 (0.43, 0.73)
CBZ, carbamazepine; FOL, folic acid; LTG, lamotrigine; LEV, levetiracetam; PHT, phenytoin; VPA, sodium valproate; p-value for difference in proportions of the drug prescribed
between the years 2010 and 2000.
a Signiﬁcance at 95% level after Bonferonni correction for multiple testing.
b Pearson correlation coefﬁcient over the 11 years with (95% conﬁdence intervals).
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compares AEDs prescribed in 2000 and 2001 to those prescribed in
2009 and 2010, subdivided into age groups.
460 people were co-prescribed folic acid with their ﬁrst AED.
The mean proportion of people co-prescribed folic acid with
their ﬁrst AED between 2000 and 2010 was 6.2% (of all people);
20.3% (women 14–45 years); 3.2% (everyone except women 14–
45 years); 1.5% (men 14–45 years); 3.6% (children aged 0–17
years); 3.8% (adults > 45 years). There was a signiﬁcant
difference in the proportion of folic acid co-prescribed to
women aged 14–45 years when compared to all other patients
(p-value < 0.001). There was no signiﬁcant change over time in
the proportion of folic acid prescribed to the cohort as a whole
or to any of the sub-groups.
4. Discussion
We have demonstrated changes in the choice of ﬁrst AED for
new onset epilepsy between 2000 and 2010 in Wales. There was a
trend for more prescriptions of lamotrigine and levetiracetam and
fewer prescriptions of phenytoin and carbamazepine as a ﬁrst
AED. The increased use of lamotrigine may reﬂect better
tolerability with similar efﬁcacy when compared to carbamaze-
pine in patients with focal seizures.2 Levetiracetam’s increasing
use as a ﬁrst choice AED since its introduction in the UK in 2000
can be explained by its efﬁcacy in the treatment of generalised and
focal epilepsies and its low rate of drug interactions, when
compared with other AEDs.
Sodium valproate taken in pregnancy is associated with an
increased rate of major congenital malformations (MCMs).3 There
is also increasing evidence that sodium valproate exposure during
pregnancy is associated with a decrease in cognitive abilities in
early childhood.4 Lamotrigine and levetiracetam are associatedwith signiﬁcantly lower rates of MCMs.3,8 Prescribers’ knowledge
of this could explain our observation that women of childbearing
age and girls are prescribed signiﬁcantly less sodium valproate as a
ﬁrst-line AED and correspondingly more lamotrigine and levetir-
acetam.
It is well established that periconceptual folic acid supplemen-
tation reduces the risk of neural tube defects in the general
population. However, the current UK national guidelines stating
that women with epilepsy on AEDs who may become pregnant
should receive folic acid, are based on a lower level of evidence.5 To
our knowledge, there were no publications during the study period
producing positive evidence for folic acid supplementation during
pregnancy in women with epilepsy. Indeed one study found no
advantage in taking preconceptual folic acid.9 This may explain
why we did not see a signiﬁcant change in the co-prescription of
folic acid. This may now change, as patients and doctors become
increasingly aware of evidence showing that maternal pericon-
ceptual folic acid may positively inﬂuence cognitive abilities in
early childhood.4
It was not possible to record epilepsy type in this study;
thus, some of the changing prescribing trends may have been
due to a change in diagnosis of epilepsy syndrome. Folic acid is
available ‘‘over the counter’’ and so some women may be taking
folic acid even though they are not receiving a prescription from
their GP. We have not captured AED prescriptions issued in
hospitals in this study, however, this is likely to be a small
proportion of total AED prescriptions in Wales. We have not
distinguished between women aged 14 and 45 years who may
or may not become pregnant – knowing that a woman of
childbearing age is deﬁnitely not going to get pregnant can
inﬂuence AED choice.
Two UK based studies looking at AED use in children and
adults showed similar trends for increasing lamotrigine and
W.O. Pickrell et al. / Seizure 23 (2014) 77–8080levetiracetam and decreasing valproate and phenytoin use,
particularly in women.10,11 An Australian study looking at AED
use between 2003 and 2008 showed the same trends, apart from
increasing use of sodium valproate.12 To our knowledge, this is
the ﬁrst study to analyse speciﬁcally the trends of ﬁrst time
prescription of AEDs and concurrent folic acid prescription in
the last decade.
In conclusion, we identiﬁed a change in the ﬁrst AED prescribed
for epilepsy in Wales between 2000 and 2010. There was
signiﬁcantly more lamotrigine and levetiracetam prescribed and
signiﬁcantly less sodium valproate prescribed to women of
childbearing age and girls. The number of women co-prescribed
folic acid did not change signiﬁcantly during this time. These
changing prescribing trends, particularly in women of childbearing
age, are reassuring given that they reﬂect published evidence in
terms of AED efﬁcacy, tolerability and safety.
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